par Solinas, Cinzia 
;De Silva, Pushpamali;Bron, Dominique ;Willard-Gallo, Karen ;Sangiolo, Dario
Référence Seminars in oncology
Publication Publié, 2019-02-01
;De Silva, Pushpamali;Bron, Dominique ;Willard-Gallo, Karen ;Sangiolo, DarioRéférence Seminars in oncology
Publication Publié, 2019-02-01
Article révisé par les pairs
| Résumé : | Targeting inhibitory immune checkpoint molecules has dramatically changed treatment paradigms in medical oncology. Understanding the best strategies to unleash a pre-existing immune response or to induce an efficient immune response against tumors has emerged as a research priority. In this work, we focus on a novel target for cancer immunotherapy, the inhibitory receptor T-cell immunoglobulin and mucin domain 3 (TIM3). This narrative review describes TIM3 biology in different (tumor-infiltrating) immune cells, particularly in the immunosuppressive regulatory T cells and dysfunctional/exhausted cytotoxic T lymphocytes, but also in cells that confer innate immunity – natural killer and dendritic cells. We discuss the functional role of TIM3, its expression and its clinical significance in a variety of tumors, and confront the heterogeneous results emerging from different studies, including clinical trials of immunotherapy. Finally, this work summarizes the principal early-phase clinical trials exploring TIM3 blockade and discusses some future perspectives. |
